These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2825067)

  • 1. Lack of effect of 28 days of neuroleptic treatment on platelet benzodiazepine binding sites in schizophrenics.
    Tanne Z; Weizman R; Karp L; Katz Y; Tyano S; Gavish M
    Neuropsychobiology; 1987; 17(3):121-3. PubMed ID: 2825067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased peripheral benzodiazepine binding sites in platelets of neuroleptic-treated schizophrenics.
    Gavish M; Weizman A; Karp L; Tyano S; Tanne Z
    Eur J Pharmacol; 1986 Feb; 121(2):275-9. PubMed ID: 2870930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet serotonin-2 receptors in schizophrenia: effects of illness and neuroleptic treatment.
    Pandey SC; Sharma RP; Janicak PG; Marks RC; Davis JM; Pandey GN
    Psychiatry Res; 1993 Jul; 48(1):57-68. PubMed ID: 8105499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral-type benzodiazepine-binding sites in platelets of schizophrenics with and without tardive dyskinesia.
    Weizman R; Tanne Z; Karp L; Tyano S; Gavish M
    Life Sci; 1986 Aug; 39(6):549-55. PubMed ID: 3016444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients.
    DeLisi LE; Wise CD; Bridge TP; Rosenblatt JE; Wagner RL; Morihisa J; Karson C; Potkin SG; Wyatt RJ
    Psychiatry Res; 1981 Feb; 4(1):95-107. PubMed ID: 6111821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients.
    Weizman R; Tanne Z; Granek M; Karp L; Golomb M; Tyano S; Gavish M
    Eur J Pharmacol; 1987 Jun; 138(2):289-92. PubMed ID: 3040435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased density of peripheral benzodiazepine binding sites on platelets of currently drinking, but not abstinent alcoholics.
    Suranyi-Cadotte B; Lafaille F; Dongier M; Dumas M; Quirion R
    Neuropharmacology; 1988 Apr; 27(4):443-5. PubMed ID: 2843780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of increasing estradiol levels on platelet peripheral benzodiazepine binding sites in women undergoing human menopausal gonadotropin treatment.
    Diorio DL; Welner SA; Tulandi T; Lal S; Suranyi-Cadotte BE
    Neuropsychobiology; 1990-1991; 23(4):169-72. PubMed ID: 1966624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in peripheral benzodiazepine receptors in patients with panic disorder and obsessive-compulsive disorder.
    Marazziti D; Rotondo A; Martini C; Giannaccini G; Lucacchini A; Pancioli-Guadagnucci ML; Diamond BI; Borison R; Cassano GB
    Neuropsychobiology; 1994; 29(1):8-11. PubMed ID: 8127425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haem precursor effects on [3H]-PK 11195 binding to platelets.
    Odber J; Cutler M; Dover S; Moore MR
    Neuroreport; 1994 May; 5(9):1093-6. PubMed ID: 8080964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Predicting the effect of psychopharmacotherapy in schizophrenic patients].
    Dikiĭ NT
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(1):110-5. PubMed ID: 6121436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet monoamine-oxidase activity in schizophrenia. Relation to genetic load of the illness and treatment with antipsychotic drugs.
    Kemali D; Maj M; Ariano MG; Salvati A
    Encephale; 1985; 11(1):31-4. PubMed ID: 2859981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The platelet polyphosphoinositide system in schizophrenia: the effects of neuroleptic treatment.
    Essali MA; Das I; de Belleroche J; Hirsch SR
    Biol Psychiatry; 1990 Sep; 28(6):475-87. PubMed ID: 1977477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol--new addition to the drug treatment of schizophrenia.
    Stewart A; Lafave HG; Segovia G
    Behav Neuropsychiatry; 1969 Oct; 1(7):23-8. PubMed ID: 4907607
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy.
    Gattaz WF; Köllisch M; Thuren T; Virtanen JA; Kinnunen PK
    Biol Psychiatry; 1987 Apr; 22(4):421-6. PubMed ID: 3567258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive changes in acute schizophrenia with brief neuroleptic treatment.
    Wahba M; Donlon PT; Meadow A
    Am J Psychiatry; 1981 Oct; 138(10):1307-10. PubMed ID: 7294185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral benzodiazepine receptors in platelets of epileptic patients.
    Larkin JG; McKee PJ; Thompson GG; Brodie MJ
    Br J Clin Pharmacol; 1993 Jul; 36(1):71-4. PubMed ID: 8396957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.